{"pmid":32352407,"title":"Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","text":["Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.","J Clin Invest","Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan","32352407"],"abstract":["Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases."],"journal":"J Clin Invest","authors":["Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352407","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1172/JCI139642","e_drugs":["Catecholamines"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495698075648,"score":9.490897,"similar":[{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":140.21175},{"pmid":32425294,"pmcid":"PMC7227559","title":"Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.","text":["Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.","A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \"Cytokine Storm Syndrome\" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS.","Blood Rev","England, James T","Abdulla, Alym","Biggs, Catherine M","Lee, Agnes Y Y","Hay, Kevin A","Hoiland, Ryan L","Wellington, Cheryl L","Sekhon, Mypinder","Jamal, Shahin","Shojania, Kamran","Chen, Luke Y C","32425294"],"abstract":["A subset of patients with severe COVID-19 develop profound inflammation and multi-organ dysfunction consistent with a \"Cytokine Storm Syndrome\" (CSS). In this review we compare the clinical features, diagnosis, and pathogenesis of COVID-CSS with other hematological CSS, namely secondary hemophagocytic lymphohistiocytosis (sHLH), idiopathic multicentric Castleman disease (iMCD), and CAR-T cell therapy associated Cytokine Release Syndrome (CRS). Novel therapeutics targeting cytokines or inhibiting cell signaling pathways have now become the mainstay of treatment in these CSS. We review the evidence for cytokine blockade and attenuation in these known CSS as well as the emerging literature and clinical trials pertaining to COVID-CSS. Established markers of inflammation as well as cytokine levels are compared and contrasted between these four entities in order to establish a foundation for future diagnostic criteria of COVID-CSS."],"journal":"Blood Rev","authors":["England, James T","Abdulla, Alym","Biggs, Catherine M","Lee, Agnes Y Y","Hay, Kevin A","Hoiland, Ryan L","Wellington, Cheryl L","Sekhon, Mypinder","Jamal, Shahin","Shojania, Kamran","Chen, Luke Y C"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425294","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.blre.2020.100707","keywords":["covid-19","cytokine release syndrome","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","idiopathic multicentric castleman disease","severe acute respiratory syndrome coronavirus -2 (sars-cov-2)"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837925519360,"score":136.03242},{"pmid":32446778,"title":"The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.","text":["The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.","In 2019-2020 a new coronavirus named SARS-CoV-2 was identified as the causative agent of a several acute respiratory infection named COVID-19, which is causing a worldwide pandemic. There are still many unresolved questions regarding the pathogenesis of this disease and especially the reasons underlying the extremely different clinical course, ranging from asymptomatic forms to severe manifestations, including the Acute Respiratory Distress Syndrome (ARDS). SARS-CoV-2 showed phylogenetic similarities to both SARS-CoV and MERS-CoV viruses, and some of the clinical features are shared between COVID-19 and previously identified beta-coronavirus infections. Available evidence indicate that the so called \"cytokine storm\" an uncontrolled over-production of soluble markers of inflammation which, in turn, sustain an aberrant systemic inflammatory response, is a major responsible for the occurrence of ARDS. Chemokines are low molecular weight proteins with powerful chemoattractant activity which play a role in the immune cell recruitment during inflammation. This review will be aimed at providing an overview of the current knowledge on the involvement of the chemokine/chemokine-receptor system in the cytokine storm related to SARS-CoV-2 infection. Basic and clinical evidences obtained from previous SARS and MERS epidemics and available data from COVID-19 will be taken into account.","Cytokine Growth Factor Rev","Coperchini, Francesca","Chiovato, Luca","Croce, Laura","Magri, Flavia","Rotondi, Mario","32446778"],"abstract":["In 2019-2020 a new coronavirus named SARS-CoV-2 was identified as the causative agent of a several acute respiratory infection named COVID-19, which is causing a worldwide pandemic. There are still many unresolved questions regarding the pathogenesis of this disease and especially the reasons underlying the extremely different clinical course, ranging from asymptomatic forms to severe manifestations, including the Acute Respiratory Distress Syndrome (ARDS). SARS-CoV-2 showed phylogenetic similarities to both SARS-CoV and MERS-CoV viruses, and some of the clinical features are shared between COVID-19 and previously identified beta-coronavirus infections. Available evidence indicate that the so called \"cytokine storm\" an uncontrolled over-production of soluble markers of inflammation which, in turn, sustain an aberrant systemic inflammatory response, is a major responsible for the occurrence of ARDS. Chemokines are low molecular weight proteins with powerful chemoattractant activity which play a role in the immune cell recruitment during inflammation. This review will be aimed at providing an overview of the current knowledge on the involvement of the chemokine/chemokine-receptor system in the cytokine storm related to SARS-CoV-2 infection. Basic and clinical evidences obtained from previous SARS and MERS epidemics and available data from COVID-19 will be taken into account."],"journal":"Cytokine Growth Factor Rev","authors":["Coperchini, Francesca","Chiovato, Luca","Croce, Laura","Magri, Flavia","Rotondi, Mario"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32446778","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.cytogfr.2020.05.003","keywords":["covid-19","cxcl10","cxcl8","chemokines","coronavirus","cytokine storm"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667698385850728449,"score":117.71982},{"pmid":32482373,"title":"Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","text":["Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.","Arch Med Res","Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib","32482373"],"abstract":["Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab."],"journal":"Arch Med Res","authors":["Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482373","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.arcmed.2020.05.009","keywords":["covid-19","cytokine storm syndrome","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668532114882035712,"score":116.688965},{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490384941057,"score":116.56524}]}